Synbio Technologies LLC services

Immunogenicity or Human Anti-Mouse Antibodies (HAMA) response is what happens when antibodies derived from xenogeneic sources are administered to humans. This can potentially decrease the effectiveness of immune-treatment through rapid clearance of the therapeutic antibody or immune-conjugate. In some cases, the patient may even develop an allergic sensitivity and be at risk of anaphylactic shock upon any future treatment containing these “foreign” antibodies. Due to this potential risk of immunogenicity and HAMA response, the humanization of antibodies from xenogeneic sources to become safer and more reliable humanized antibody drugs is critical.

Complex structures and high production costs associated with monoclonal antibodies (mAbs) have limited their achievable clinical applications. For this reason, scientists focusing on antibody drug discovery have shifted their interests toward recombinant antibody fragments.

Obtaining the hybridoma monoclonal antibody (mAb) sequence is one of the key requirements of recombinant antibody engineering. Synbio Technologies provides both accurate and efficient monoclonal antibody sequencing services. To accomplish this, we utilize special primer sets and advanced sequencing techniques to help our customers save on research costs and increase overall efficiency. In doing so, we allow our customers to accomplish their downstream research goals and applications such as antibody humanization, antibody reformatting, or cell line transfection.

The immune system is a very robust “antibody factory” that consistently produces antibodies to fight infections and diseases by recognizing and targeting infected cells or pathogens (antigens). The emergence of single B cell antibody technology has enabled a new strategy for discovery of naturally occurring antibody drugs. The single B cell antibody technology produces higher throughput and higher coverage than the conventional hybridoma or phage display technologies. Most importantly, this technology also avoids the disadvantage of unnaturally paired heavy and light antibody chain displayed by phage.

The binding affinity of an antibody is one of the key parameters to determine the efficacy and dosage of an antibody drug. Currently, the methods for improving the binding affinity of antibodies mainly focus on site-mutation, CDR rearrangement, DNA recombinant, etc. With our unique and effective affinity maturation technology, we can quickly spot the key amino acid site in antibody domain. This, in turn, increases the binding affinity of the antibody, reaching at least nM level.